Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study

Open access
Gururangan, Sridharan, Fangusaro, Jason, Poussaint, Tina Young, McLendon, Roger E., Onar-Thomas, Arzu, Wu, Shengjie, Packer, Roger J., Banerjee, Anu, Gilbertson, Richard J., Fahey, Frederic, Vajapeyam, Sridhar, Jakacki, Regina, Gajjar, Amar, Goldman, Stewart, Pollack, Ian F., Friedman, Henry S., Boyett, James M., Fouladi, Maryam, Kun, Larry E.·2014·Neuro-Oncology

Abstract

BACKGROUND: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent low-grade glioma to measure sustained response and/or stable disease lasting ≥6 months and progression-free survival. METHODS: Thirty-five evaluable patients received 2 doses (10 mg/kg each) of single-agent BVZ intravenously 2 weeks apart and then BVZ + CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included neuroimaging and expression of tumor angiogenic markers (vascular endothelial growth factor [VEGF], VEGF receptor 2, hypoxia-inducible factor 2α, and carbonic anhydrase 9). RESULTS: Thirty-five evaluable patients (median age 8.4 y [range, 0.6-17.6]) received a median of 12 courses of BVZ + CPT-11 (range, 2-26). Twenty-nine of 35 patients (83%) received treatment for at least 6 months. Eight patients progressed on treatment at a median time of 5.4 months (range, 1-17.8). Six patients (17.7%) still in follow-up have had stable disease without receiving additional treatment for a median of 40.1 months (range, 30.6-49.3) from initiating therapy. The 6-month and 2-year progression-free survivals were 85.4% (SE ± 5.96%) and 47.8% (SE ± 9.27%), respectively. The commonest toxicities related to BVZ included grades 1-2 hypertension in 24, grades 1-2 fatigue in 23, grades 1-2 epistaxis in 18, and grades 1-4 proteinuria in 15. The median volume of enhancement decreased significantly between baseline and day 15 (P < .0001) and over the duration of treatment (P < .037). CONCLUSION: The combination of BVZ + CPT-11 appears to produce sustained disease control in some children with recurrent low-grade gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/not154

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 163

Metadata

Authors
Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., Fahey, F., Vajapeyam, S., Jakacki, R., Gajjar, A., Goldman, S., Pollack, I. F., Friedman, H. S., Boyett, J. M., Fouladi, M., & Kun, L. E.
Venue
Neuro-Oncology
Published
2013-12-04
Volume
16
Issue
2
Pages
310-317
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2108817973
Cited by
163
References
1
FWCI
5.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. https://app.cochat.ai/papers/10.1093/neuonc/not154
The paper
Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., Fahey, F., Vajapeyam, S., Jakacki, R., Gajjar, A., Goldman, S., Pollack, I. F., Friedman, H. S., Boyett, J. M., Fouladi, M., & Kun, L. E. (2014). Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro-Oncology. https://doi.org/10.1093/neuonc/not154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.